Related Experiment Video
Updated: Dec 20, 2025
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
Identification and characterization of mammaglobin-A epitope in heterogenous breast cancers for enhancing
Zhiqiang Liu1, Xiqin Yang2, Cuimi Duan2
1Beijing Institute of Basic Medical Sciences, 27 Taiping Road, Haidian District, Beijing, 100850, China. zhiqiangliu_amms@163.com.
Abstract:
Although targeted therapy has been extensively investigated for breast cancers, a molecular target with broad application is currently unavailable due to the high heterogeneity of these cancers. Mammaglobin-A (Mam-A), which is overexpressed in most breast carcinomas, has been proposed as a promising target. However, the lack of specific targeting moieties due to uncertain binding epitopes hampers further translational study. Here, seven potential epitopes of Mam-A were disclosed, and a unique epitope was then identified in most types of breast cancers, despite the genotypic heterogeneity. With phage display technology, the epitope was determined to be N-terminal amino acids 42-51 of Mam-A (N42-51). Then, the N42-51 epitope-specific monoclonal antibody, mAb785, was conjugated to poly lactic-co-glycolic acid (PLGA) nanoparticles loaded with therapeutic agents, thereby enhancing the drug uptake and therapeutic efficacy in different genotypes of breast cancers. The computer simulation of the N42-51 epitope and the mAb785 structures, as well as their interactions, further revealed the specific targeting mechanism of the mAb785-conjugated nanoparticles to breast cancers.
Insights
Researchers identified a specific epitope on Mammaglobin-A (Mam-A), a protein overexpressed in breast cancer. This discovery enabled the development of targeted nanoparticles for improved breast cancer therapy across various genotypes.
Area of Science:
- Oncology
- Molecular Biology
- Nanotechnology
Background:
- Breast cancer exhibits significant heterogeneity, limiting the broad applicability of targeted therapies.
- Mammaglobin-A (Mam-A) is overexpressed in most breast carcinomas, presenting a potential therapeutic target.
- Identifying specific binding epitopes for Mam-A is crucial for developing targeted therapies.
Purpose of the Study:
- To identify a unique and broadly applicable epitope on Mammaglobin-A (Mam-A) for targeted breast cancer therapy.
- To develop and evaluate Mam-A-targeted nanoparticles for enhanced drug delivery and efficacy.
Main Methods:
- Phage display technology was employed to identify potential Mam-A epitopes.
- A unique epitope, N-terminal amino acids 42-51 (N42-51), was identified.
- An N42-51-specific monoclonal antibody (mAb785) was developed and conjugated to poly lactic-co-glycolic acid (PLGA) nanoparticles.
Main Results:
- A unique N42-51 epitope on Mam-A was identified, present across diverse breast cancer genotypes.
- mAb785-conjugated PLGA nanoparticles demonstrated enhanced drug uptake and therapeutic efficacy.
- Computer simulations confirmed the specific targeting mechanism of mAb785-conjugated nanoparticles to breast cancer cells.
Conclusions:
- The N42-51 epitope represents a promising, broadly applicable target for breast cancer therapy.
- mAb785-conjugated nanoparticles offer a novel strategy for targeted drug delivery in breast cancer.
- This approach holds potential for improving therapeutic outcomes in patients with various breast cancer genotypes.
